Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Affimed N.V. (AFMDQ)
Mannheim, DE
Affimed N.V. operates as a clinical-stage biopharmaceutical firm, dedicated to the discovery and advancement of immunotherapies targeting cancer across both the United States and Germany. Its primary therapeutic candidates include AFM13, which has successfully concluded Phase 2 trials for CD30-positive lymphoma, Phase 1b for Hodgkin lymphoma, and Phase 2b clinical evaluation for peripheral T-cell lymphoma. Another key candidate, AFM24, a tetravalent, bispecific innate cell engager designed to bind epidermal growth factor receptor and CD16A, is currently undergoing a Phase 2a clinical trial for patients with advanced malignancies. Additionally, AFM28, another innate cell engager (ICE), is in preclinical stages for addressing acute myeloid leukemia. Similarly, AFM32, an ICE candidate, is progressing through preclinical development for solid tumor indications. The company also maintains a collaborative partnership with Artiva Biotherapeutics, aiming to develop the combined therapy of acimtamig and AlloNK. Furthermore, a licensing and strategic alliance with Roivant Sciences Ltd. focuses on the development and commercialization of new ICE molecules, notably AFM32, within the field of oncology. A strategic collaboration with Genentech is also in place for advancing specific product candidates, encompassing novel NK cell engager-based immunotherapeutic agents designed to combat a range of cancers. Formerly named Affimed Therapeutics B.V., the entity adopted its current moniker, Affimed N.V., in October 2014. Established in 2000, its corporate headquarters are situated in Mannheim, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.66% | -100.00% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
7.50
+7,499,900.0%
|
-
Revenue growth Biotechnology: +1.6%-80.0% Q3'24: -92.1% (vs Q3'23)
-
EPS growth Biotechnology: +29.7%-17.4% Q3'24: +42.3% (vs Q3'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,426.8% Q3'24: -7,187.1% (vs Q3'23)
-
EBIT margin Biotechnology: +0.0%-1,258.4% Q3'24: -9,594.2% (vs Q3'23)
-
ROIC Biotechnology: -16.1%-2,444.3% Q3'24: -1,156.4% (vs Q3'23)
-
Share dilution Biotechnology: -3.4%+4.9% Q3'24: +7.8% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.19× Q3'24: -0.22× (vs Q3'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.79M
est.
|
8.17M
est.
|
2.33M
2.33M – 2.33M
-71.5% YoY
|
2.33M
2.33M – 2.33M
+0.0% YoY
|
2.33M
2.33M – 2.33M
+0.0% YoY
|
2.33M
2.33M – 2.33M
+0.0% YoY
|
| EBITDA |
-1.79M
est.
|
-8.17M
est.
|
-2.33M
-2.33M – -2.33M
+71.5% YoY
|
-2.33M
-2.33M – -2.33M
+0.0% YoY
|
-2.33M
-2.33M – -2.33M
+0.0% YoY
|
-2.33M
-2.33M – -2.33M
+0.0% YoY
|
| EBIT |
-1.79M
est.
|
-8.17M
est.
|
-2.33M
-2.33M – -2.33M
+71.5% YoY
|
-2.33M
-2.33M – -2.33M
+0.0% YoY
|
-2.33M
-2.33M – -2.33M
+0.0% YoY
|
-2.33M
-2.33M – -2.33M
+0.0% YoY
|
| Net Income |
-60.59M
est.
|
-25.99M
est.
|
-27.77M
-27.77M – -27.77M
-6.9% YoY
|
-24.15M
-24.15M – -24.15M
+13.0% YoY
|
-19.47M
-19.47M – -19.47M
+19.4% YoY
|
-10.72M
-10.72M – -10.72M
+45.0% YoY
|
| SGA |
1.90M
est.
|
8.69M
est.
|
2.48M
2.48M – 2.48M
-71.5% YoY
|
2.48M
2.48M – 2.48M
+0.0% YoY
|
2.48M
2.48M – 2.48M
+0.0% YoY
|
2.48M
2.48M – 2.48M
+0.0% YoY
|
| EPS |
-4.06
est.
|
-1.74
est.
|
-1.86
-1.86 – -1.86
-6.9% YoY
|
-1.62
-1.62 – -1.62
+13.0% YoY
|
-1.30
-1.30 – -1.30
+19.4% YoY
|
-0.72
-0.72 – -0.72
+45.0% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wolfgang Fischer | MD, Chief Operating Officer, Chief Strategy Officer & Member of Management Board | 632.0K | — |
| Andreas Harstrick | Chief Medical Officer & Member of Management Board | 522.8K | — |
| Alexander Fudukidis | Head of Investor Relations & Director of Investor Relations | — | male |
| Mary Beth Sandin | Vice President of Marketing & Communications | — | — |
| Melvyn Little | Founder & Consultant | — | — |
| Michael Wolf | Head of Finance & Administration | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AFMDQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
